RESEARCH ARTICLE

Placental dysfunction is associated with altered microRNA expression in pregnant women with low folate status

Bernadette C. Baker1, Fiona L. Mackie2, Samantha C. Lean1, Susan L. Greenwood1, Alexander E. P. Heazell1, Karen Forbes3 and Rebecca L. Jones1

1 Maternal and Fetal Health Research Centre, University of Manchester, Manchester, UK
2 Centre of Women's and Newborn's Health & Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK
3 Division of Reproduction and Early Development, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK

Scope: Low maternal folate status during pregnancy increases the risk of delivering small for gestational age (SGA) infants, but the mechanistic link between maternal folate status, SGA, and placental dysfunction is unknown. microRNAs (miRNAs) are altered in pregnancy pathologies and by folate in other systems. We hypothesized that low maternal folate status causes placental dysfunction, mediated by altered miRNA expression.

Methods and results: A prospective observational study recruited pregnant adolescents and assessed third trimester folate status and placental function. miRNA array, QPCR, and bioinformatics identified placental miRNAs and target genes. Low maternal folate status is associated with higher incidence of SGA infants (28% versus 13%, p < 0.05) and placental dysfunction, including elevated trophoblast proliferation and apoptosis (p < 0.001), reduced amino acid transport (p < 0.01), and altered placental hormones (pregnancy-associated plasma protein A, progesterone, and human placental lactogen). miR-222-3p, miR-141-3p, and miR-34b-5p were upregulated by low folate status (p < 0.05). Bioinformatics predicted a gene network regulating cell turnover. Quantitative PCR demonstrated that key genes in this network (zinc finger E-box binding homeobox 2, v-myc myelocytomatosis viral oncogene homolog (avian), and cyclin-dependent kinase 6) were reduced (p < 0.05) in placentas with low maternal folate status.

Conclusion: This study supports that placental dysfunction contributes to impaired fetal growth in women with low folate status and suggests altered placental expression of folate-sensitive miRNAs and target genes as a mechanistic link.

Keywords: fetal growth / folate deficiency / gene expression / microRNA / placental dysfunction

Additional supporting information may be found in the online version of this article at the publisher’s web-site

1 Introduction

Poor maternal nutritional status increases the risk of adverse pregnancy outcomes, particularly fetal growth restriction (FGR) or small for gestational age (SGA) infants [1]. Critically, this links maternal nutritional state with increased risk of stillbirth and neonatal death, as well as intrapartum

VEGFA, vascular endothelial growth factor A; ZEB, zinc finger E-box binding homeobox
and postnatal complications, and neurodevelopmental problems in childhood [2, 3]. In addition, there is a strong association between SGA birth and higher risk of diseases in adulthood, including cardiovascular disease and metabolic syndrome [4, 5].

The mechanisms underlying increased susceptibility to FGR/SGA are unclear; while caloric and macronutrient insufficiencies may have direct consequences on fetal growth, inadequate levels of micronutrients are likely to have more complex indirect effects, either on the fetus or placenta [6]. Folate is a critical nutrient for one carbon metabolism that produces nucleotide bases for DNA synthesis and repair, and the universal methyl donor S-adenosylmethionine for methylation processes [7]. Folate deficiency results in impaired cell survival and division, genomic instability, and dysregulated DNA/protein methylation. Therefore, adequate folate supply is critical during pregnancy, not only for preventing neural tube defects, but for normal fetal growth and development. Indeed, inadequate maternal folate concentrations are related to the birth of SGA infants [8–10].

Pregnant adolescents are a population susceptible to low folate status, due at least in part to inadequate dietary folate consumption; this in turn is strongly related to risk of SGA birth in this population [8]. Despite this association, the mechanisms responsible are unclear. Placental dysfunction is an established underlying cause of SGA [11], thus we hypothesized that inadequate third trimester maternal folate status impacts fetal growth by adversely affecting placental function during the period of maximal fetal growth.

To test this hypothesis, we collected maternal serum and placental samples from well-characterized adolescent pregnancies and analyzed placental function according to third trimester maternal folate status. We investigated placental expression of known and novel folate-sensitive microRNAs (miRNAs) as a potential posttranslational mechanism linking low maternal folate status and placental dysfunction. Differential expression of placental miRNAs has been reported in FGR and in vitro studies have shown various miRNAs affect trophoblast proliferation, invasion, and survival [12]. There are no studies in pregnancy linking folate status and miRNA expression, but in vivo and in vitro studies in other systems have demonstrated that folate deficiency alters miRNA expression [13, 14]. The current study identifies a key involvement of the placenta in mediating the adverse effects of low maternal folate status on the developing fetus, and highlights dysregulation of placental miRNAs as a potential underpinning mechanism.

2 Materials and methods

2.1 Teenage Nutrition Study

Pregnant adolescents (16–18 years, n = 77) were recruited to Teenage Nutrition Study (TEENS) between 28 and 40 weeks gestation from St Mary’s Hospital or local community antenatal clinics, Manchester. Exclusion criteria included multiple pregnancy, known fetal anomalies, or obstetric/medical complications, which may affect nutritional status. At recruitment, maternal venous blood was taken for endocrine analyses and to assess folate status. Demographic data, obstetric history, and lifestyle information including self-reported folic acid/nutritional supplementation were recorded. Obstetric outcome data were collected and the individualized birthweight centile (IBC) was calculated using GRO Weight Centile Calculator version 7.4.2 (Gestation Network 2009). SGA was defined as IBC < 10th centile [15]. The TEENS study was granted ethical approval by the North West REC (08/H1010/55). Written informed consent was obtained from all participants. Placentas from participants in the TEENS study were collected at delivery and used for all described analyses of placental function. Data and maternal serum samples from a further cohort of pregnant adolescents (n = 80, selected based on third trimester red blood cell (RBC) folate concentrations), previously recruited to the About Teenage Eating study (03/CM/32) [8], were included for obstetric outcome and endocrine analyses only. Placental samples were not obtained from this cohort. The same inclusion and exclusion criteria applied.

2.2 Analysis of maternal folate status

Maternal folate status was assessed as RBC folate (reflective of long-term tissue folate content [16]) and serum folate by the Clinical Biochemistry Department at Manchester Royal Infirmary. Folate deficiency is defined as serum folate <10 nmol/L or RBC folate <340 nmol/L based on elevated plasma homocysteine as a metabolic indicator of deficiency [17]. Whether these thresholds apply to pregnant women is disputed, as folate demands are elevated in pregnancy and the association between low folate and SGA extends beyond this threshold [8]. On the basis of our previous findings [8], and that folate concentrations below 453 nmol/L (200 µg/L) are clinically treated in our obstetric population, we defined low folate status as RBC <453 nmol/L.

2.3 Placental collection and sampling

Placentas were collected from a subgroup of TEENS participants (n = 46) within 30 min of delivery, and trimmed placental weight recorded. Villous tissue samples (2 cm³) were excised using a systematic uniform random sampling system [18] from four placental locations to minimize regional variation in gene expression [19]. Samples were pooled prior to further dissection and randomly subdivided for histological, molecular, and nutrient transport analyses. A nested case-control study was utilized for placental analyses, with low and adequate folate status cohorts selected to match most closely on demographic and biophysical characteristics. Sample sizes
were dictated by power calculations based on previous studies [20].

2.4 Immunohistochemistry

Immunohistochemistry was performed on 5 μm sections of formalin-fixed wax-embedded villous tissue from three regions/placenta using colorimetric detection as described [21]. Mouse monoclonal primary antibodies used to detect proliferation and apoptosis were anti-Ki67 (0.16 μg/mL, Dako, Ely, UK) and anti-M30 (1 μg/mL, Roche, Hertfordshire, UK), respectively, with nonimmune mouse IgG as a negative control. Ten random images per section were captured using an Olympus BX41 microscope (Olympus, UK), QICAM Fast 1394 camera (QImaging, Canada), and Image Pro-Plus version 7.0 (Bethesda, Media Cybernetics). Proliferative and apoptotic indices were calculated by manual counting of Ki67+/M30+ trophoblasts divided by total nuclear count [21].

2.5 System A activity

Sodium-dependent uptake of 14C-methylaminoisobutyric acid (PerkinElmer, Buckinghamshire, UK) was measured to assess amino acid transporter system A activity in placental fragments as described [20]. The rate of uptake over 10–30 min was calculated and normalized for fragment protein content.

2.6 Placental endocrine function

ELISAs for placental hormones (human chorionic gonadotropin (hCG), progesterone, human placental lactogen (hPL), and pregnancy-associated plasma protein A (PAPP-A)) were performed on third trimester maternal serum (low folate: n = 57, adequate folate: n = 100), according to manufacturer’s instructions (DRG Diagnostics, Germany), using a Versamax plate reader (Molecular Devices, CA, USA) at 450 nm using SoftMax Pro (Molecular Devices). Inter-and intraassay variabilities were 4.3–9.9% and 2.6–5.5%, respectively.

2.7 Real-time PCR

Real-time PCR was performed to quantify expression of genes encoding system A transporters, placental hormones, or predicted miRNA targets. Placental RNA (200 ng, RNAeasy kit; Qiagen) was reverse transcribed (AffinityScript multiple temperature cDNA synthesis kit, Agilent, Berkshire, UK) and QPCR performed using Brilliant SYBR III Green QPCR Master Mix (Agilent) with 5-carboxy-x-rhodamine as the reference dye in a Stratagene MX3000P real time PCR machine. Specific primers used are presented in Supporting Information Table 1. Data were normalized for expression of housekeeping gene TATA box binding protein as 2−ΔCT.

Candidate miRNAs were amplified by QPCR in placental RNA samples (Supporting Information Table 2, n = 11/group), extracted using mirVana miRNA isolation kit (Ambion), and selected based on known regulation by folate (mirR222, mirR22, mirR122, and mirR302a). Reverse transcription of RNA (25 ng) was performed using miRCURY LNA Universal RT microRNA PCR system (Exiqon, Vedbaek, Denmark), with a UniSp6 RNA spike-in template included as an internal QC to monitor the reaction efficiency QPCR was carried out using ExilENT SYBR Green master mix (Exiqon) with LNA-specific primer sets (Exiqon; Supporting Information Table 3) and reference dye 5-carboxy-x-rhodamine. Data were normalized to 5S rRNA or U6 snRNA as housekeeping genes as 2−ΔCT.

2.8 miRNA array profiling

miRNA profiling on a subset of samples from TEENS with adequate and low folate status (Supporting Information Table 4, n = 7/group) was performed by Exiqon using the miRCURY LNA microRNA Array 7th Gen (Exiqon), containing capture probes targeting all human miRNAs registered in mirBASE 18.0 (Vedbaek, Denmark). Benjamini and Hochberg multiple testing correction was applied, using the software R/bioconductor, to calculate the adjusted p-values where a value <0.05 was considered significant [22]. QPCR validation studies on selected candidate miRNAs were performed as above on the same sample set used in section 2.7 for targeted analyses of folate-sensitive miRNAs.

2.9 Bioinformatic analysis of miRNA array targets

Network generation was performed on identified folate-regulated miRNAs using Ingenuity Knowledge Base (Ingenuity® Pathway Analysis, Qiagen, Redwood City, www.qiagen.com/ingenuity) to identify potential gene targets of the miRNAs and explore their connectivity, filtering to only include experimentally validated data. Experimentally validated gene targets of selected miRNAs were retrieved from high-quality manually curated literature databases—miRTarBase Release 4.5 [23] and TARBASE version 7.0 [24].

2.10 Statistics

Statistical analyses were performed using GraphPad Prism (version 6.0). Demographic and obstetric outcome data were analyzed using Mann–Whitney U test, Spearman’s correlation or Fisher’s exact test. Data from placental and serum analyses were analyzed using Mann–Whitney U test,
Table 1. Demographic data of overall study participants

<table>
<thead>
<tr>
<th>Category</th>
<th>Adequate folate status (n = 100)</th>
<th>Low folate status (n = 57)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>18 (15–18.8)</td>
<td>17.7 (15–18.9)</td>
<td>NS</td>
</tr>
<tr>
<td>Gynecological age (years)</td>
<td>4.9 (1.0–9.6)</td>
<td>5.0 (2.0–9.1)</td>
<td>NS</td>
</tr>
<tr>
<td>Ethnicity n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caucasian</td>
<td>69 (69%)</td>
<td>33 (57.9%)</td>
<td>NS</td>
</tr>
<tr>
<td>Other</td>
<td>31 (31%)</td>
<td>24 (42.1%)</td>
<td>N</td>
</tr>
<tr>
<td>Primiparous n (%)</td>
<td>94 (94%)</td>
<td>56 (98.2%)</td>
<td>NS</td>
</tr>
<tr>
<td>Smoking status n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Smoker</td>
<td>31 (31%)</td>
<td>24 (42.1%)</td>
<td>NS</td>
</tr>
<tr>
<td>Non-smoker</td>
<td>69 (69%)</td>
<td>33 (58.9%)</td>
<td>NS</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>22.5 (14.8–42.3)</td>
<td>22.3 (15.4–40.8)</td>
<td>NS</td>
</tr>
<tr>
<td>Gestation at delivery (weeks)</td>
<td>40.1 (35.9–42.0)</td>
<td>40.3 (36.0–43.1)</td>
<td>NS</td>
</tr>
<tr>
<td>Birthweight (g)</td>
<td>3300 (2020–4460)</td>
<td>3200 (2000–4160)</td>
<td>NS</td>
</tr>
<tr>
<td>Individualized birthweight centile (IBC)</td>
<td>40 (0–99)</td>
<td>28 (0–98)</td>
<td>0.05</td>
</tr>
<tr>
<td>Male infant n (%)</td>
<td>45 (45%)</td>
<td>27 (47.5%)</td>
<td>NS</td>
</tr>
<tr>
<td>Serum folate (nmol/L)</td>
<td>14.7 (2.7–51.0)</td>
<td>7.7 (3.4–17.0)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>RBC folate (nmol/L)</td>
<td>948.3 (455.5–1602.1)</td>
<td>385.2 (219.8–449.0)</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

Data are median (range). Mann–Whitney or Fisher’s exact test. RBC, red blood cell.

Spearman’s correlation, or linear regression. Results were considered significant if p < 0.05.

3 Results

3.1 Demographic data

The demographic characteristics of the total study participants (TEENS and About Teenage Eating, n = 157) are present in Table 1. As per experimental design, both serum and RBC folate concentrations were different between groups (p < 0.0001) with no other differences apparent. The participants included in placental analyses (only from the TEENS study) were matched for demographic characteristics and did not differ from those of the total study group, with the exception of maternal BMI at time of booking to antenatal care, which was lower in women with low folate status (p < 0.05; Supporting Information Table 5).

3.2 Low folate status and pregnancy outcome

Adolescents with low folate status delivered infants with a lower IBC (p < 0.05) and a higher proportion of SGA infants than those with adequate folate status (32% versus 13%, p < 0.05) (Table 2). RBC folate concentration and IBC positively correlated (r = 0.2164, p < 0.01). No significant differences were detected in unadjusted birthweight, low birthweight < 2500 g, large for gestational age infants, or gestation at delivery. Placental weight was unaffected by maternal folate status (not shown).

Table 2. Relationship between third trimester maternal RBC folate status and pregnancy outcome

<table>
<thead>
<tr>
<th>Category</th>
<th>Adequate (n = 100)</th>
<th>Low (n = 57)</th>
<th>p</th>
<th>Correlation</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Birthweight (g)</td>
<td>3300 (2020–4460)</td>
<td>3200 (2000–4160)</td>
<td>NS</td>
<td>0.04051</td>
<td>NS</td>
</tr>
<tr>
<td>IBC</td>
<td>39.9 (0–99)</td>
<td>27.8* (0–98)</td>
<td>0.05</td>
<td>0.2164**</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Gestation at delivery</td>
<td>40.1 (35.9–42.0)</td>
<td>40.3 (36.0–43.1)</td>
<td>NS</td>
<td>−0.1083</td>
<td>NS</td>
</tr>
<tr>
<td>SGA n (%)</td>
<td>13 (13.1%)</td>
<td>18** (32.1%)</td>
<td>&lt;0.01</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LGA n (%)</td>
<td>7 (7.0%)</td>
<td>4 (7.1%)</td>
<td>NS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LBW n (%)</td>
<td>5 (5.1%)</td>
<td>8 (14.3%)</td>
<td>0.068</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Median (range) value stated. Groups compared using Fisher’s exact or Mann–Whitney test; relationship between continuous variables analyzed with Spearman’s correlation. *p < 0.05, **p < 0.01.

IBC, individualized birthweight centile; SGA, small for gestational age; LGA, large for gestational age; LBW, low birthweight.
3.3 Impact of maternal folate status on placental cell turnover

Low maternal folate status was associated with elevated trophoblast proliferation ($p < 0.01$) and apoptosis ($p < 0.001$) compared to placentas from adolescents with adequate folate status (Fig. 1). Both proliferative ($r = -0.359, p < 0.05$) and apoptotic ($r = -0.426, p < 0.01$) indices negatively correlated with RBC folate.

3.4 Impact of maternal folate status on placental nutrient transport

System A activity was significantly lower in placentas from adolescents with low compared to adequate folate status ($p < 0.01$; Fig. 2). There was no effect of maternal folate status on nonspecific sodium-independent $^{14}$C-methylaminoisobutyric acid uptake (not shown). Placental mRNA expression of one of the system A isoforms (SLC38A4, $p < 0.01$) was lower with low folate status, while SLC38A1 and 2 were unchanged between groups (Fig. 2).

3.5 Impact of maternal folate status on placental endocrine function

Maternal serum concentrations of placental hormones were measured in the third trimester (Fig. 3). PAPP-A, progesterone, and hPL increased with advancing gestation ($p < 0.01$). Linear regression showed that PAPP-A and progesterone concentrations were higher in women with low folate status ($p < 0.05$ and $p < 0.01$ respectively), while hPL was lower ($p < 0.01$). hCG concentrations were unchanged.

© 2017 The Authors. Molecular Nutrition & Food Research Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim. www.mnf-journal.com
Figure 2. Effect of maternal folate status on placental amino acid transport. (A) System A activity (sodium-dependent $^{14}$C-methylaminoisobutyric acid ($^{14}$C-MeAIB) uptake) in placental fragments. Mean ± SEM; **$p < 0.01$, linear regression. Placental mRNA expression of system A isoforms: (B) SLC38A1, (C) SLC38A2, and (D) SLC38A4. Data are $2^{-\Delta\Delta CT}$ normalized for (E) TBP (TATA box binding protein). Line represents median, **$p < 0.01$, Mann–Whitney test. $n = 12$ (adequate), $n = 10$ (low folate status).

across gestation and between folate groups (not shown). Placental mRNA expression of the peptide hormones, PAPP-A, hPL, hCG (β subunit), and 3β-hydroxysteroid dehydrogenase (progesterone biosynthetic enzyme) was unaffected by folate status (Supporting Information Fig. 1).

3.6 Effect of maternal folate status on expression of known folate-sensitive miRNAs

miR-222-3p expression was higher in placentas from adolescents with low folate status ($p < 0.05$) and negatively correlated with RBC folate ($r = -0.4908$, $p < 0.05$) (Fig. 4A and C). miR-22-5p was unaffected by maternal folate status (Fig. 4B), while placental expression of miR-302a and -122 was below the limit of PCR detection (not shown).

3.7 Identification of folate-sensitive miRNAs in placenta

miRNA array expression profiling identified 16 miRNAs that were differentially expressed by maternal folate status.

© 2017 The Authors. Molecular Nutrition & Food Research Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim. www.mnf-journal.com
Interestingly, these differences were only apparent between placentas from adolescents with folate status at the higher range of adequate folate status (>1000 nM; “adequate-high” on Fig. 5) and those with low folate status. The remaining three samples in the adequate group were all from women with folate concentrations between 888 and 965 nM and they had no clear clustering on the heatmap. The 16 miRNAs were all significantly upregulated (p < 0.05) by low folate status and included trophoblast-specific miRNAs: miR-523-3p, miR-518c-3p, and miR-515-3p. miR222 was altered by low folate status, but this narrowly failed to reach statistical significance in this sample set (p = 0.06). Six miRNAs (26a-5p, 29c-3p, 30e-3p, 34b-5p, 141–3p, and 515-3p) were selected for QPCR validation studies on the basis of high expression by trophoblast cells (determined by performing PCR screens on isolated placental cell types, data not shown) and their previously reported association with pregnancy pathologies [25, 26]. While no significant differences were detected in 26a-5p, 29c-3p, 30e-3p, or 515-3p expression between groups by QPCR, miR-141-3p and miR-34b-5p were confirmed to
be expressed at higher levels in placentas from women with low folate status \((p < 0.05, \text{Fig. 6})\). Negative correlations were detected between RBC folate and miR141-3p \((r = -0.457, p < 0.05)\) or miR-34b-5p \((r = -0.439, p < 0.05)\) expression (Spearman’s correlation; Fig. 6).

3.8 Bioinformatic analyses of folate-sensitive miRNAs

Network generation performed initially on the 16 miRNAs significantly altered from the array revealed biological connectivity between key genes, cyclin-dependent kinase 6 (CDK6), v-myc avian myelocytomatosis viral oncogene homolog (MYC), phosphatase and tensin homolog, and insulin (Supporting Information Fig. 2). These genes are known to be important for placental function and fetal growth.

3.8.1 Gene targets of miR-222-3p, miR-34b-5p, and miR-141-3p

Known (experimentally validated) target genes of miR-222-3p, 34b-5p, and 141–3p identified by data mining were refined to 11 genes based on reported association with pregnancy pathologies and/or folate status (Table 3). Genes altered by both folate status and in placentas from FGR pregnancies included MYC \([25, 26]\), vascular endothelial growth factor A (VEGFA) \([27, 28]\), BCL2-like 11 (BCL2L11/BIM) \([28, 29]\), cyclin-dependent kinase inhibitor 1C (CDKN1C/p57) \([25, 28]\),
and tumor protein 53 (TP53) [28, 30]. Other gene targets associated with placental pathologies include homeobox genes zinc finger E-box binding homeobox 1 (ZEB1) and ZEB2 [31] and insulin-like growth factor 2 [32]. Many of these genes are targeted by more than one of the candidate miRNAs, therefore the interactions between miRNAs and gene targets were explored by Ingenuity Pathway network analysis. The generated network demonstrated biological connectivity between target genes, in particular TP53, MYC, and CDK6 (Fig. 7). The predicted functional effect of this network is regulation of cell proliferation and survival.

### 3.8.2 Expression of predicted targets of folate-sensitive miRNAs in placentas from women with low folate status

QPCR analysis of genes (ZEB2 \( p < 0.01 \), MYC \( p < 0.05 \), and CDK6 \( p < 0.05 \)) identified by bioinformatics analysis as known targets of the folate-sensitive miRNAs demonstrated reduced expression in placentas from adolescents with low maternal folate status (Fig. 8). Positive correlations between maternal RBC folate and ZEB2 \( r = 0.611, p < 0.01 \), MYC \( r = 0.496, p < 0.05 \), and CDK6 \( r = 0.631, p < 0.05 \); Spearman’s
Table 3. Gene targets for folate-sensitive miRNAs

<table>
<thead>
<tr>
<th>Gene symbol</th>
<th>Gene name</th>
<th>Validated miRNA target(s)</th>
<th>Predicted miRNA target</th>
<th>Altered in pregnancy pathologies</th>
<th>Altered by folate status</th>
</tr>
</thead>
<tbody>
<tr>
<td>MYC</td>
<td>v-myc myelocytomatosis viral oncogene homolog (avian)</td>
<td>34b-5p 222–3p</td>
<td></td>
<td>↑ mRNA in FGR placenta [25]</td>
<td>↑ in liver of folate-deficient rat model [26]</td>
</tr>
<tr>
<td>ZEB 2</td>
<td>zinc finger E-box binding homeobox 2</td>
<td>141-3p 222-3p</td>
<td>34b-5p</td>
<td>↓ uterine tissue mouse model of PTB [31]</td>
<td></td>
</tr>
<tr>
<td>CDK6</td>
<td>Cyclin-dependent kinase 6</td>
<td>34b-5p 141-3p 222-3p</td>
<td></td>
<td>Placental expression positively correlates with birthweight [48]</td>
<td></td>
</tr>
<tr>
<td>VEGF A</td>
<td>Vascular endothelial growth factor A</td>
<td>34b-5p 141-3p</td>
<td></td>
<td>↑ in FGR placenta [27]</td>
<td>↑ or ↓ in folate deficient cells [28]</td>
</tr>
<tr>
<td>BCL2</td>
<td>B-cell CLL/lymphoma 2</td>
<td>34b-5p 141-3p 222-3p</td>
<td></td>
<td>↑ in FGR/PE placenta [29]</td>
<td></td>
</tr>
<tr>
<td>BCL2L11</td>
<td>BCL2-like 11 (apoptosis facilitator, BIM)</td>
<td>222-3p 34b-5p 141-3p</td>
<td></td>
<td>↑ in FGR placenta [29]</td>
<td>↑ with folate deficiency [28]</td>
</tr>
<tr>
<td>CDKN1B</td>
<td>Cyclin-dependent kinase inhibitor 1B (p27, Kip1)</td>
<td>222-3p 34b-5p 141-3p</td>
<td></td>
<td>↑ in PE placenta [53]</td>
<td>↑ with folate deficiency [28]</td>
</tr>
<tr>
<td>CDKN1C</td>
<td>Cyclin-dependent kinase inhibitor 1C (p57, Kip2)</td>
<td>222-3p 34b-5p 141-3p</td>
<td></td>
<td>↑ in PE/FGR placenta [25,53]</td>
<td>↑ with folate deficiency [28]</td>
</tr>
<tr>
<td>TP53</td>
<td>Tumor protein p53</td>
<td>222-3p 34b-5p 141-3p</td>
<td></td>
<td>↑ in FGR placenta [30]</td>
<td>↑ and ↓ with folate deficiency [28]</td>
</tr>
<tr>
<td>ZEB 1</td>
<td>Zinc finger E-box binding homeobox 1</td>
<td>141-3p</td>
<td></td>
<td>↓ in uterine tissue mouse model of PTB [31]</td>
<td></td>
</tr>
<tr>
<td>IGF2</td>
<td>Insulin like growth factor 2</td>
<td>141-3p</td>
<td></td>
<td>Placental specific K/O mouse models have FGR pups [32]</td>
<td></td>
</tr>
</tbody>
</table>

Experimentally validated and putative targets of miRNAs, and association with folate deficiency and/or pregnancy complications. FGR, fetal growth restriction; IBC, individualized birthweight centile; K/O, knock-out; PE, preeclampsia; PTB, preterm birth.

correlation) mRNA expression were detected. Expression of TP53 and VEGF A were unchanged by maternal folate status.

4 Discussion

This study extends our previous observations associating third trimester low maternal folate status with impaired fetal growth [8], supporting the hypothesis that placental dysfunction underlies this process. We demonstrated abnormalities in trophoblast proliferation and apoptosis, nutrient transport, and endocrine function in adolescents with low folate status, and proposed altered miRNA expression as a potential post-transcriptional mechanism.

The placental phenotype in adolescents with low folate status closely resembles pregnancies complicated by FGR/SGA, including elevated trophoblast apoptosis [30] and reduced system A activity [33, 34]. Increased apoptosis occurs in trophoblast cultured under folate-deficient conditions or treated with homocysteine to mimic biochemical consequences of folate deficiency [35, 36]. In contrast to FGR [30], we observed elevated proliferation in women with low folate status but in concordance with increased trophoblast proliferation in placentas of compromised fetuses with reduced movements [37] and preeclamptic pregnancies [38]. This may reflect placental compensatory responses promoting fetal growth, observed with maternal iron deficiency anemia or smoking [39]. Reduced system A activity with low maternal folate
status is consistent with observations in both animal models and women with lower maternal nutritional status [20, 34]. Placental gene expression of major system A isoforms, SLC38A1 and SLC38A2 [40], were unchanged by maternal folate status, suggesting posttranscriptional mechanisms were operating. In contrast, placental SLC38A4 expression was reduced with low folate status, consistent with reports of specific altered mRNA expression in a mouse model of FGR [41] and in women administered synthetic glucocorticoids antenatally [42]. The functional consequences of altered SLC38A4 are questionable, however, as the relative contribution of this isoform to overall system A activity in term placentas is very low [40]. In common with FGR/SGA, hPL concentrations were significantly lower in low folate status women [43, 44]. The elevated concentrations of PAPP-A and progesterone in women with low folate status imply specific alterations in placental endocrinology, not simply changed placental mass.

Our investigation of posttranscriptional mechanisms for placental dysfunction focused on miRNAs. Although some known folate-sensitive miRNAs were unaltered in our study, expression of miR-222-3p was increased in placentas from low folate status women, consistent with reported upregulation in T lymphocytes in response to folate deficiency [13]. Using an unbiased miRNA array, 16 miRNAs, including miR-34b-5p and miR-141-3p, were altered with...
low folate status, potentially suggesting these novel folate-sensitive miRNAs provide a mechanistic posttranscriptional link between maternal folate levels and placental dysfunction. Altered expression of miR-222-3p and miR-141-3p has been reported in pregnancy pathologies [12, 45], specifically miR-141-3p expression is upregulated in FGR placentas. The likely mechanism for elevated miRNA expression under low folate conditions is promoter hypomethylation due to reduced levels of methyl donor S-adenosylmethionine [46]. This is supported by altered methylation and expression of
placental miRNAs in a calorie-restricted mouse model of FGR [47].

Bioinformatics analysis identified predicted gene targets of the folate-sensitive miRNAs, including genes regulating cell cycle and apoptosis (e.g., TP53, BCL2, MYC, CDKN1B/C, and TNFSF10), consistent with the elevated trophoblast apoptosis observed. Other target genes (e.g., VEGFA, MMP1, insulin-like growth factor 2) are involved in tissue remodeling, angiogenesis, and placental development, indicating additional placental functions may be affected by maternal folate status. Higher miRNA expression would reduce expression of downstream target genes in placentas from folate-deficient women; this was confirmed for ZEB2, MYC, and CDK6 at the mRNA level. Placental CDK6 expression positively correlates with birthweight [48], implying reduced expression under low folate conditions would negatively affect fetal growth. Reduced MYC and unaltered TP53 expression in placentas from women with low folate status contrast with FGR pregnancies, where both are elevated [25, 26, 30]. This may reflect differences in the placental molecular phenotypes underlying FGR (e.g., hypoxia related to utero-placental insufficiency versus folate deficiency).

Many putative gene targets are regulated by multiple folate-sensitive miRNAs, strengthening evidence for their involvement in placental dysfunction and possible additive effects where multiple miRNAs target the same gene. Several target genes have the capacity to regulate diverse downstream networks, as transcription factors, for example, MYC, or phosphatases that modulate cellular signaling (e.g., phosphatase and tensin homolog), potentially amplifying the effect of low folate status on placental function.

A strength of this study is stratification of women based on RBC folate concentration, a more stable marker than serum folate levels, reflecting folate status over a 3-month period. Study limitations concern the time between blood folate analysis and placental functional measurements at term and variability between subjects, particularly in miRNA studies that are highly susceptible to environmental and fetal parameters (e.g., smoking and fetal gender) [49, 50]. This is likely to underlie the discrepancy in the array and PCR findings for miR222, whose upregulation narrowly failed to reach significance on the smaller sample set analyzed by array, and the fact that only two of the six miRNAs identified by array were successfully validated by QPCR. In vitro manipulation of trophoblast folate status would reduce confounding influences providing definitive evidence of direct regulation of miRNAs and target genes by intracellular folate content.

This unique observational study links miRNA expression with folate deprivation in pregnancy highlighting the importance of adequate folate status throughout pregnancy to protect against SGA/FGR. These observations were made using a threshold of 453 nmol/L to define low folate status, and this was validated by our detection of higher rates of SGA births and placental dysfunction below these concentrations. Optimal RBC folate concentrations for fetal growth have not been defined and our observation of clustering of placental miRNA profiles in women with folate status >1000 nM may imply that, at least at a molecular level, adequate folate concentrations for normal placental function greatly exceed those defined for deficiency status in nonpregnant women. This is consistent with recent evidence suggesting that levels >900 nmol/L maximize reduction in occurrence of neural tube defects [17] and protect against uracil misincorporation and apoptosis [51].

In summary, we demonstrate that placental functions critical to optimal fetal growth are altered in adolescents with low folate status in late pregnancy, and this is associated with altered miRNA expression. Whether miRNA mis-expression also occurs in the fetus is unknown, but it is a potential mechanism for developmental programing as described in animal models of maternal undernutrition [52]. Although the current study was conducted on pregnant adolescents, we believe the findings are applicable to the wider obstetric population, reinforcing the need for further mechanistic studies on the impact of maternal nutritional status on the placenta.

This study funded by Wellcome Trust Value in People Scheme, Manchester Biomedical Research Centre and the Maternal and Fetal Health Research Centre is supported by Tommy’s, an Action Medical Research Endowment and the Greater Manchester Comprehensive Research Network. IPA licence supported by the Wellcome Trust (097820/Z/11/B). We thank Cara Taylor, Gina Bennett and the midwives at St. Mary’s Hospital for their assistance with recruitment and sample collection, and the young women for donating tissue samples to research. Thanks to Ainslie Garrod for technical assistance.


The authors have declared no conflict of interest.

5 References


[51] Fenech, M., Folate (vitamin B9) and vitamin B12 and their function in the maintenance of nuclear and mitochondrial genome integrity. Mutat. Res. 2012, 733, 21–33.
